Blood Disorder Program: Prevention, Surveillance, and Research
Active
- Assistance listing
- 93.080
- Agency
-
Centers for Disease Control and Prevention
Department of Health and Human Services
- Grant awards
- 22 $43,908,939 in federal obligations
Program facts
- Also known as
- Division of Blood Disorders - Prevention, Surveillance and Research
- Assistance type
-
- Cooperative Agreement
- Treasury account
-
- 75-0958-1-1-550
- More information
Program details come from SAM.gov Assistance Listings. Updated . Grant award figures come from USAspending.gov.
About this program
The Centers for Disease Control and Prevention (CDC) funds state and local blood disorder prevention, surveillance, and research programs through Assistance Listing 93.080, with the most recent award disbursed September 30, 2023.
The program supports planning, development, implementation, coordination, and evaluation of blood disorder activities by state health agencies and public, private, and nonprofit organizations. Funded activities include surveillance and epidemiological work to set priorities and direct health promotion interventions; establishment of national, state, or local prevention infrastructure; training fellowships for geneticists, epidemiologists, and clinicians in public health practice; and dissemination of prevention information across state and local agencies and private-sector partners. Recent awards exemplify this scope: a $26 million surveillance program (Community Counts Public Health Surveillance for Bleeding Disorders, 2015) that monitored hemophilia treatment centers nationwide; sickle cell disease data collection initiatives in California ($1.88 million, 2020) and multiple states beginning 2019 to build surveillance capacity; and transfusion-complications research for thalassemia and sickle cell disease ($1.77 million and $1.75 million, respectively, 2019).
All awards in the portfolio are Cooperative Agreements. The CDC accounts for 100 percent of funding across 22 awards totaling $43.9 million obligated since 2014. Award frequency is irregular—eight awards in 2014, 11 in 2019, and one each in 2015, 2020, and 2023—but the program remains active.
Project periods run 1 to 5 years with initial 12-month budget cycles; recipients may continue non-competitively subject to satisfactory progress. Typical award magnitudes range from $60 thousand (capacity-building activities) to multi-million-dollar surveillance platforms, though a $26 million award represents a significant outlier.
Two opportunities have closed. CDC-RFA-DD-23-0002 (Sickle Cell Data Collection Program) posted July 19, 2022, with a due date of May 11, 2023, and offered five-year funding periods; applicants included state governments, nonprofit and for-profit organizations, tribes, and higher education institutions. CDC-RFA-DD20-2002 (Evaluation of Health Promotion and Prevention Programs for Blood Disorders) posted August 13, 2019, with a May 15, 2020 due date, supporting hemophilia, von Willebrand disease, venous thromboembolism, and thalassemia prevention and education programs across comparable applicant categories. No current solicitation is open.
Objective and description
- Objective
To work with State health agencies and other public, private, and nonprofit organizations in planning, development, implementation, coordination, or evaluation of programs or other activities related to improved blood disorders. To provide a nationa
- Description
To work with State health agencies and other public, private, and nonprofit organizations in planning, development, implementation, coordination, or evaluation of programs or other activities related to improved blood disorders. To provide a national, State or local focus for the prevention of conditions in persons with blood disorders; to employ epidemiological methods to set priorities, build capacity and direct health promotion interventions for persons with blood disorders. To expand public health training opportunities through fellowships to introduce geneticists, epidemiologists, and clinicians to public health practice through education, training and career-enhancing experiences.
Eligibility
- Applicant eligibility
Full and open competition
- Uses of assistance
Funds may be used to strengthen, to expand, to build upon or to enhance surveillance, health promotion, education and training, prevention/intervention activities that contribute to the mission and activities of the Division of Blood Disorders. Funds may be used to improve and strengthen State and local public health infrastructure by providing technical assistance to other appropriate health agencies, organizations, special groups or coalitions. Funds may be used to support capacity building, program planning, development, implementation, evaluation, and surveillance for blood disorders outcomes, including related health promotion, education and training, and prevention/intervention. Funds may also be used to coordinate the dissemination of prevention information to the general public, target populations and among state and local agencies and public and private sector organizations in the United States.
- Length and time phasing of assistance
Financial assistance is provided for a 12-month budget period with a period of performance of up to five years subject to the availability of funds and satisfactory progress of the recipient.
How to apply
- Criteria for selecting proposals
Applications will be evaluated on the review criteria described in the Notice of Funding Opportunity Announcements (NOFOs). In general, the review and selection process of complete and responsive applications to the NOFO consists of determination of the scientific and technical merit by objective or peer review, availability of funds, and relevance of program priorities and the priorities of CDC.
- Award procedure
After review and approval, a Notice of Award (NoA) will be prepared and processed, along with appropriate notification to the public. Initial awards provide funds for the first budget period (usually 12 months) and the NoA will indicate support recommended for the remainder of the project period, allocation of Federal funds by budget categories, award requirements, and special conditions, if any.Cooperative agreement awards and grants, competitive and single eligibility, are determined by an internal objective committee review process at CDC, including peer reviews for research activities. Awards will be based on evaluation criteria set forth in the respective Notice of Funding Opportunity, the availability of funds, and such other significant factors as deemed necessary and appropriate by CDC.
- Renewals
Project period of performance is 1 to 5 years. After initial awards, and subject to availability of funds, projects may be continued non-competitively contingent upon satisfactory progress by the recipient (as documented in required reports) and the determination that continued funding is in the best interest of the Federal government.
Grant opportunities
Grant awards
Latest 10 of 22 listed here. See the rest on GovTribe.
Top recipients by federal obligations
| Rank | Recipient | Federal obligations | Share |
|---|---|---|---|
| 1 | American Thrombosis & Hemostasis Network Inc. | $26,000,000 | 59% |
| 2 | The National Bleeding Disorders Foundation | $3,928,636 | 9% |
| 3 | Hemophilia Federation Of America, Inc. | $3,473,165 | 8% |
| 4 | National Blood Clot Alliance | $2,739,090 | 6% |
| 5 | Public Health Institute | $2,074,084 | 5% |
| 6 | Georgia State University Research Foundation Inc. | $1,967,639 | 4% |
| 7 | The Regents Of The University Of California. San Francisco | $1,749,438 | 4% |
| 8 | Cooley's Anemia Foundation | $1,200,000 | 3% |
| 9 | Center For Public Health Innovation | $286,510 | 1% |
| 10 | Michigan Department Of Health And Human Services | $85,000 | <1% |
10 of 16 recipients listed here. See the rest on GovTribe.
Federal obligations by fiscal year
| Fiscal year | Federal obligations |
|---|---|
| FY2026 | $2,900,000 |
| FY2024 | $8,934,119 |
| FY2023 | $16,929,278 |
| FY2022 | $26,411,547 |
| FY2021 | $11,222,427 |
| FY2020 | $17,115,888 |
| FY2019 | $14,140,368 |
| FY2018 | $6,058,045 |
| FY2017 | $6,058,045 |
| FY2016 | $5,958,045 |
| FY2015 | $5,958,045 |
| FY2014 | $963,995 |
Show all 12
Quick answers
What is Assistance Listing 93.080?
Assistance Listing 93.080 is Blood Disorder Program: Prevention, Surveillance, and Research, a federal grant program run by Centers for Disease Control and Prevention (Department of Health and Human Services).
What is the CFDA number for Blood Disorder Program: Prevention, Surveillance, and Research?
Its CFDA number is 93.080: Assistance Listing numbers were called CFDA numbers before 2018.
How much funding has Assistance Listing 93.080 awarded?
22 grant awards under 93.080 have obligated $43,908,939 in federal funds to 16 recipients.
Who receives the most funding from 93.080?
The recipients obligated the most under Blood Disorder Program: Prevention, Surveillance, and Research are American Thrombosis & Hemostasis Network Inc. ($26,000,000), The National Bleeding Disorders Foundation ($3,928,636) and Hemophilia Federation Of America, Inc. ($3,473,165).
Are there open grant opportunities under 93.080?
No opportunity listed under 93.080 is open now. The latest, Sickle Cell Data Collection Program, was posted on July 19, 2022.
On GovTribe
See this program's full record
- Every grant award and opportunity under it
- Funding by recipient, agency and assistance type
- Alerts for new opportunities
- Ask GovTribe AI about this program